Tania Reuter

TL;DR: Once-daily dolutegravir, in combination with up to two other antiretroviral drugs, is well tolerated with greater virological effect compared with twice-daily raltegravIR in this treatment-experienced patient group.

TL;DR: The results reveal a still small prevalence of infection in the study area, despite the significant number of sick people overloading the health system, and indicate an important underreporting in the area and a frequency that still can grow, making necessary public health actions for the containment of the transmission.

TL;DR: Most patients are cirrhotic, present high prevalence of cardiometabolic diseases and esophageal varices, reduced HRQoL mainly in terms of pain/discomfort, and work productivity impairment, especially presenteeism, and it is demonstrated that hepatitis C virus imposes an economic burden on Brazilian Health Care System and that most of this cost is due to drug treatment.

TL;DR: A guideline for diagnosis and treatment of hepatitis B is elaborate, which includes information regarding the population to be tested, diagnostic tools, indications of treatment, therapeutic schemes and also how to handle HBV infection in specific situations (pregnancy, children, immunosuppression, etc).

TL;DR: It is unclear whether the extension of peginterferon alfa-2a/ribavirin treatment may benefit HCV genotype 2/3 patients who do not achieve RVR, and the study was stopped early because recruitment was slower than anticipated.